Clinical Trial Update: Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial updates safety and efficacy of BAY 50-4798 in HIV infection, reporting early results from HIV-infected patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BAY 50-4798

Snippet

Sponsor: Bayer | Conditions: HIV Infections | Phase 1, Phase 2 | Status: COMPLETED